Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.56 |
| ▸ | HRH2 | P25021 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 7/20 | 0.50 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23928166 | 1.00 | HRH3 (0.56) | HRH3HRH2HRH1LTA4HTLR7 | |
| SCHEMBL23928129 | 1.00 | HRH3 (0.56) | HRH3HRH2HRH1LTA4HTLR7 | |
| SCHEMBL23928107 | 0.90 | HRH3 (0.50) | HRH3HRH2HRH1LTA4H | |
| SCHEMBL28386934 | 0.82 | LTA4H (0.57) | HRH3HRH2HRH1LTA4H | |
| SCHEMBL23963302 | 0.82 | LTA4H (0.57) | HRH3HRH2HRH1LTA4H | |
| SCHEMBL23963274 | 0.82 | LTA4H (0.57) | HRH3HRH2HRH1LTA4H | |
| SCHEMBL23291139 | 0.81 | HRH3 (0.54) | HRH3HRH2HRH1LTA4H | |
| SCHEMBL23928187 | 0.81 | HRH3 (0.54) | HRH3HRH2HRH1LTA4H | |
| SCHEMBL3231519 | 0.80 | LTA4H (0.52) | HRH3LTA4H | |
| SCHEMBL2242246 | 0.80 | LTA4H (0.52) | HRH3LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814356-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ADORA2A, ADORA1, ADORA3 | HRH3 416/4885HRH2 257/4885HRH1 393/4885 |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | HRH3 416/4885HRH2 257/4885HRH1 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.